Novel discoveries in understanding the complexities of epilepsy and major depression.
The 39th Annual meeting of the Society for Neuroscience was held in Chicago, Illinois, USA from 17 to 21 October, 2009. The conference was attended by more than 33,000 delegates from across the globe including scientists from both basic and clinical settings. Co-incidentally, this year, the scientific community is commemorating the 200th anniversary of the birth of the famous English naturalist and biologist, Charles Darwin, who described the theory of natural selection. Keeping its traditions, the congress discussed various new advances in the area of neuroscience. The topics were divided into symposia, mini-symposia, nano-symposia, special lectures and poster sessions. The main areas of discussion were novel discoveries in Alzheimer's, Parkinson's, drug addiction, autism, epilepsy and major depression. According to the WHO, neurological disorders are one of the greatest threats to public health. There are many unknown and challenging facts in the field of neuroscience that needs exploration. It is unfortunate that despite the availability of various drugs for treating these disorders, a sizeable population still do not achieve complete remission. Therefore, organizing such events and addressing the latest developments may open new treatment vistas for patients suffering from these disorders. The present review discusses some of the outcomes of the deliberations in the field of epilepsy and major depression.
Dhir
Ashish
A
University of California, Davis Medical Center, Department of Neurology, Sacramento, California 95817, USA. ashish.dhir@ucdmc.ucdavis.edu
D000280:Administration, Inhalation; D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D004921:Erythropoietin / Q000627:therapeutic use; D005971:Glutamates / Q000502:physiology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000473:pathology; D043882:Receptors, Cannabinoid / Q000187:drug effects / Q000502:physiology; D011994:Recombinant Proteins; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D051153:Wnt Proteins / Q000502:physiology
D018759:Adrenergic Uptake Inhibitors; D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D000928:Antidepressive Agents; D018765:Dopamine Uptake Inhibitors; D004921:Erythropoietin; D005971:Glutamates; D043882:Receptors, Cannabinoid; D011994:Recombinant Proteins; D017367:Selective Serotonin Reuptake Inhibitors; D051153:Wnt Proteins